Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

Pacira BioSciences Reports Preliminary Net Product Sales of $50.2 Million for July 2022

Globe Newswire - Wed Aug 10, 2022

-- EXPAREL average daily sales for July 2022 were 105 percent of July 2021 --

TAMPA, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of $50.2 million for the month of July 2022. The company’s net product sales include EXPAREL^® (bupivacaine liposome injectable suspension), ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), and the iovera° system. The company began recognizing sales of ZILRETTA in November 2021 after completing its acquisition of Flexion Therapeutics, Inc.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

number cruncher

U.S technology stocks with earnings and price momentum

report on business

Lightspeed Commerce stock soars on better-than-expected profit forecast

GameStop, AMC continue to slide as meme stocks rally loses steam

The close: Dow briefly hits 40,000 milestone, TSX rises on upbeat earnings

report on business

Proxy advisers recommend investors vote ‘no’ on Shopify executive pay

The close: Wall Street boasts fresh records as inflation data fuels rate-cut bets

Chevron tops Tesla as most-shorted stock in April, says Hazeltree

The close: Nasdaq at record high after Fed chair’s comments but TSX dips for third day